# US 11,110,069 B2 · Composition comprising cannabinoids for relief of pain > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,110,069 B2 - Document ID: US11110069B2 - Status: Granted - Kind: B2 - Application number: 16/671,469 - Filed: 2019-11-01 - Published: 2020-05-07 - Granted: 2021-09-07 - Earliest claimed: 2018-11-02 - Assignees: Tweed Inc. - Applicants: Canopy Health Innovations - Inventors: Mark Andrew Hetherington; Chris Schnarr - Web page: https://patentgrep.com/patent/US11110069B2 ## CPC - A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol} - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil - A61K 31/606: having amino groups - A61K 31/618: having the carboxyl group in position 1 esterified, e.g. salsalate - A61K 36/185: Magnoliopsida (dicotyledons) - A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea - A61K 36/3482: {Cannabis} - A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject. ## Claims ### Claim 1 A composition for topical application comprising: at least one purified cannabinoid, wherein the purified cannabinoid is cannabidiol (CBD); at least one anti-inflammatory agent in an amount ranging from between about 10 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and at least one botanical extract, wherein the botanical extract is arnica. ### Claim 2 (depends on 1) The composition of claim 1, further comprising a terpene or terpenoid. ### Claim 3 (depends on 2) The composition of claim 2, wherein the terpene or terpenoid is menthol, camphor, or a combination thereof. ### Claim 4 (depends on 2) The composition of claim 2, wherein the terpene is an isolate, an extract or a distillate. ### Claim 5 (depends on 1) The composition of claim 1, further comprising a flavonoid, wherein the flavonoid is an isolate, an extract or a distillate. ### Claim 6 (depends on 1) The composition of claim 1, wherein the purified cannabinoid is present in an amount ranging from between about 0.5 wt % and about 10 wt % of the total weight of the composition. ### Claim 7 (depends on 1) The composition of claim 1, wherein the purified cannabinoid is present in an amount ranging from between about 2 wt % and about 8 wt % of the total weight of the composition. ### Claim 8 (depends on 1) The composition of claim 1, wherein the purified cannabinoid is present in an amount ranging from between about 2 wt % and about 6 wt % of the total weight of the composition. ### Claim 9 (depends on 1) The composition of claim 1, wherein the anti-inflammatory agent is present in an amount ranging from between about 10 wt % and about 25 wt % of the total weight of the composition. ### Claim 10 (depends on 1) The composition of claim 1, wherein the anti-inflammatory agent is present in an amount ranging from between about 20 wt % and about 90 wt % of the total weight of the composition. ### Claim 11 (depends on 1) The composition of claim 1, wherein the anti-inflammatory agent is present in an amount of, about 10 wt %, about 15 wt %, about 20 wt % or about 25 wt % of the total weight of the composition. ### Claim 12 (depends on 1) The composition of claim 1, wherein the botanical extract is present in an amount ranging from between about 0.5 wt % and about 90 wt % of the total weight of the composition. ### Claim 13 (depends on 1) The composition of claim 1, wherein the botanical extract is present in an amount ranging from between about 1 wt % and about 25 wt % of the total weight of the composition. ### Claim 14 (depends on 1) The composition of claim 1, wherein the botanical extract is present in an amount ranging from between about 0.5 wt % and about 10 wt % of the total weight of the composition. ### Claim 15 A composition for topical application comprising: at least one purified cannabinoid in an amount of between about 0.5 wt % and about 10 wt % of the total weight of the composition, wherein the purified cannabinoid is cannabidiol (CBD); at least one anti-inflammatory agent in an amount of and about 10 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; and at least one botanical extract in an amount of between about 1 wt % and about 25 wt % of the total weight of the composition, wherein the botanical extract is arnica. ### Claim 16 A composition for topical application comprising: at least one purified cannabinoid, wherein the purified cannabinoid is cannabidiol (CBD); at least one anti-inflammatory agent in an amount of between about 10 wt % and about 90 wt % of the total weight of the composition, wherein the anti-inflammatory agent is methyl salicylate; at least one botanical extract in an amount of between about 0.5 wt % and about 90 wt % of the total weight of the composition, wherein the botanical extract is arnica, and a terpene or terpenoid, wherein the terpene or terpenoid is menthol, camphor, or a combination thereof. ### Claim 17 (depends on 1) A method for relieving pain in a subject, the method comprising administering to the subject the composition as defined in claim 1.